Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 609086, 7 pages
http://dx.doi.org/10.1155/2014/609086
Research Article

Anti-Inflammatory Effects of the Nicotinergic Peptides SLURP-1 and SLURP-2 on Human Intestinal Epithelial Cells and Immunocytes

1Department of Dermatology, University of California, 134 Sprague Hall, Irvine, CA 92697, USA
2National Cancer Institute, Kiev 03022, Ukraine
3Department of Biological Chemistry, University of California, 134 Sprague Hall, Irvine, CA 92697, USA
4Institute for Immunology, University of California, 134 Sprague Hall, Irvine, CA 92697, USA

Received 18 March 2014; Accepted 17 April 2014; Published 4 May 2014

Academic Editor: Maryna Skok

Copyright © 2014 Alex I. Chernyavsky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Motley, J. Rhodes, S. Kay, and T. J. Morris, “Late presentation of ulcerative colitis in ex-smokers,” International Journal of Colorectal Disease, vol. 3, no. 3, pp. 171–175, 1988. View at Google Scholar · View at Scopus
  2. I. Koutroubakis, O. N. Manousos, S. G. M. Meuwissen, and A. S. Pena, “Environmental risk factors in inflammatory bowel disease,” Hepato-Gastroenterology, vol. 43, no. 8, pp. 381–393, 1996. View at Google Scholar · View at Scopus
  3. D. T. Rubin and S. B. Hanauer, “Smoking and inflammatory bowel disease,” European Journal of Gastroenterology and Hepatology, vol. 12, no. 8, pp. 855–862, 2000. View at Google Scholar · View at Scopus
  4. R. Eliakim, F. Karmeli, P. Cohen, S. N. Heyman, and D. Rachmilewitz, “Dual effect of chronic nicotine administration: augmentation of jejunitis and amelioration of colitis induced by iodoacetamide in rats,” International Journal of Colorectal Disease, vol. 16, no. 1, pp. 14–21, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. A. D. Harries, A. Baird, and J. Rhodes, “Non-smoking: a feature of ulcerative colitis,” British Medical Journal, vol. 284, no. 6317, p. 706, 1982. View at Google Scholar · View at Scopus
  6. R. F. Logan, M. Edmond, K. Somerville, and M. J. S. Lanman, “Smoking and ulcerative colitis,” British Medical Journal, vol. 288, no. 6419, pp. 751–753, 1984. View at Google Scholar · View at Scopus
  7. R. J. Motley, J. Rhodes, and G. A. Ford, “Time relationships between cessation of smoking and onset of ulcerative colitis,” Digestion, vol. 37, no. 2, pp. 125–127, 1987. View at Google Scholar · View at Scopus
  8. H. de Castella, “Non-smoking: a feature of ulcerative colitis,” British Medical Journal, vol. 284, no. 6330, p. 1706, 1982. View at Google Scholar · View at Scopus
  9. J. Birtwistle and K. Hall, “Does nicotine have beneficial effects in the treatment of certain diseases?” British Journal of Nursing, vol. 5, no. 19, pp. 1195–1202, 1996. View at Google Scholar · View at Scopus
  10. J. M. Wolf and B. A. Lashner, “Inflammatory bowel disease: sorting out the treatment options,” Cleveland Clinic Journal of Medicine, vol. 69, no. 8, pp. 621–631, 2002. View at Google Scholar · View at Scopus
  11. R. J. Hilsden, D. C. Hodgins, A. Timmer, and L. R. Sutherland, “Helping patients with Crohn's disease quit smoking,” American Journal of Gastroenterology, vol. 95, no. 2, pp. 352–358, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. G. A. Thomas, J. Rhodes, and J. R. Ingram, “Mechanisms of disease: nicotine—a review of its actions in the context of gastrointestinal disease,” Nature Clinical Practice Gastroenterology & Hepatology, vol. 2, no. 11, pp. 536–544, 2005. View at Google Scholar
  13. B. Coulie, M. Camilleri, A. E. Bharucha, W. J. Sandborn, and D. Burton, “Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 5, pp. 653–663, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. J. McGrath, J. W. McDonald, and J. K. Macdonald, “Transdermal nicotine for induction of remission in ulcerative colitis,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD004722, 2004. View at Google Scholar · View at Scopus
  15. R. D. Pullan, J. Rhodes, S. Ganesh et al., “Transdermal nicotine for active ulcerative colitis,” New England Journal of Medicine, vol. 330, no. 12, pp. 811–815, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. J. T. Green, G. A. O. Thomas, J. Rhodes et al., “Pharmacokinetics of nicotinic carbomer enemas: a new treatment modality for ulcerative colitis,” Clinical Pharmacology and Therapeutics, vol. 61, no. 3, pp. 340–348, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. J. R. Ingram, J. Rhodes, B. K. Evans, and G. A. Thomas, “Nicotine enemas for active Crohn's colitis: an open pilot study,” Gastroenterology Research and Practice, vol. 2008, Article ID 237185, 6 pages, 2008. View at Publisher · View at Google Scholar
  18. A. Bai, Y. Guo, and N. Lu, “The effect of the cholinergic anti-inflammatory pathway on experimental colitis,” Scandinavian Journal of Immunology, vol. 66, no. 5, pp. 538–545, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. C. Aldhous, R. J. Prescott, S. Roberts, K. Samuel, M. Waterfall, and J. Satsangi, “Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease?” Inflammatory Bowel Diseases, vol. 14, no. 11, pp. 1469–1482, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Qian, V. Galitovskiy, A. I. Chernyavsky, S. Marchenko, and S. A. Grando, “Plasticity of the murine spleen T-cell cholinergic receptors and their role in in vitro differentiation of nave CD4 T cells toward the Th1, Th2 and Th17 lineages,” Genes and Immunity, vol. 12, no. 3, pp. 222–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. I. Chernyavsky, J. Arredondo, V. Galitovskiy, J. Qian, and S. A. Grando, “Structure and function of the nicotinic arm of acetylcholine regulatory axis in human leukemic T cells,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 2, pp. 461–472, 2009. View at Google Scholar · View at Scopus
  22. A. I. Chernyavsky, J. Arredondo, M. Skok, and S. A. Grando, “Auto/paracrine control of inflammatory cytokines by acetylcholine in macrophage-like U937 cells through nicotinic receptors,” International Immunopharmacology, vol. 10, no. 3, pp. 308–315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Henderson, J. E. Van Limbergen, J. Schwarze, and D. C. Wilson, “Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 382–395, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. T. W. Zimmerman and H. J. Binder, “Effect of tetrodotoxin on cholinergic agonist-mediated colonic electrolyte transport,” The American Journal of Physiology, vol. 244, no. 4, pp. G386–G391, 1983. View at Google Scholar · View at Scopus
  25. A. Pettersson, S. Nordlander, G. Nylund, A. Khorram-Manesh, S. Nordgren, and D. S. Delbro, “Expression of the endogenous, nicotinic acetylcholine receptor ligand, SLURP-1, in human colon cancer,” Autonomic and Autacoid Pharmacology, vol. 28, no. 4, pp. 109–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. C. L. Green, W. Ho, K. A. Sharkey, and D. M. McKay, “Dextran sodium sulfate-induced colitis reveals nicotinic modulation of ion transport via iNOS-derived NO,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 287, no. 3, pp. G706–G714, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Sayer, J. Lu, C. Green, J. D. Söderholm, M. Akhtar, and D. M. McKay, “Dextran sodium sulphate-induced colitis perturbs muscarinic cholinergic control of colonic epithelial ion transport,” British Journal of Pharmacology, vol. 135, no. 7, pp. 1794–1800, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Jönsson, Ö. Norrgård, and S. Forsgren, “Presence of a marked nonneuronal cholinergic system in human colon: study of normal colon and colon in ulcerative colitis,” Inflammatory Bowel Diseases, vol. 13, no. 11, pp. 1347–1356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. P. L. Wei, L. J. Kuo, M. T. Huang et al., “Nicotine enhances colon cancer cell migration by induction of fibronectin,” Annals of Surgical Oncology, vol. 18, no. 6, pp. 1782–1790, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. O. Lundgren, M. Jodal, M. Jansson, A. T. Ryberg, and L. Svensson, “Intestinal epithelial stem/progenitor cells are controlled by mucosal afferent nerves,” PLoS ONE, vol. 6, no. 2, Article ID e16295, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Wei and J. Feng, “Signaling pathways associated with inflammatory bowel disease,” Recent Patents on Inflammation and Allergy Drug Discovery, vol. 4, no. 2, pp. 105–117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Sun, B. Fihn, M. Jodal, and H. Sjövall, “Effects of nicotinic receptor blockade on the colonic mucosal response to luminal bile acids in anaesthetized rats,” Acta Physiologica Scandinavica, vol. 178, no. 3, pp. 251–260, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. G. M. Roomans, V. Vanthanouvong, A. Dragomir, I. Kozlova, and R. Wróblewski, “Effects of nicotine on intestinal and respiratory epithelium,” Journal of Submicroscopic Cytology and Pathology, vol. 34, no. 4, pp. 381–388, 2002. View at Google Scholar · View at Scopus
  34. I. Kozlova, A. Dragomir, V. Vanthanouvong, and G. M. Roomans, “Effects of nicotine on intestinal epithelial cells in vivo and in vitro: an X-ray microanalytical study,” Journal of Submicroscopic Cytology and Pathology, vol. 32, no. 1, pp. 97–102, 2000. View at Google Scholar · View at Scopus
  35. I. A. Finnie, B. J. Campbell, B. A. Taylor et al., “Stimulation of colonic mucin synthesis by corticosteroids and nicotine,” Clinical Science, vol. 91, no. 3, pp. 359–364, 1996. View at Google Scholar · View at Scopus
  36. A. Cervin, S. Lindberg, U. Mercke, and R. Uddman, “Neuropeptide Y in the rabbit maxillary sinus modulates cholinergic acceleration of mucociliary activity,” Acta Oto-Laryngologica, vol. 112, no. 5, pp. 872–881, 1992. View at Google Scholar · View at Scopus
  37. F. J. Zijlstra, E. D. Srivastava, M. Rhodes et al., “EicosanoidsEffect of nicotine on rectal mucus and mucosal eicosanoids,” Gut, vol. 35, no. 2, pp. 247–251, 1994. View at Google Scholar · View at Scopus
  38. A. E. Summers, C. J. Whelan, and M. E. Parsons, “Nicotinic acetylcholine receptor subunits and receptor activity in the epithelial cell line HT29,” Life Sciences, vol. 72, no. 18-19, pp. 2091–2094, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Bencherif, P. M. Lippiello, R. Lucas, and M. B. Marrero, “Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases,” Cellular and Molecular Life Sciences, vol. 68, no. 6, pp. 931–949, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Ghia, P. Blennerhassett, R. T. El-Sharkawy, and S. M. Collins, “The protective effect of the vagus nerve in a murine model of chronic relapsing colitis,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 293, no. 4, pp. G711–G718, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. E. Ghia, P. Blennerhassett, H. Kumar-Ondiveeran, E. F. Verdu, and S. M. Collins, “The Vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model,” Gastroenterology, vol. 131, no. 4, pp. 1122–1130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Nikfar, S. Ehteshami-Ashar, R. Rahimi, and M. Abdollahi, “Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis,” Clinical Therapeutics, vol. 32, no. 14, pp. 2304–2315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J.-W. Tjiu, P.-J. Lin, W.-H. Wu et al., “SLURP1 mutation-impaired T-cell activation in a family with mal de Meleda,” British Journal of Dermatology, vol. 164, no. 1, pp. 47–53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Tsuji, K. Okamoto, Y. Matsuzaka, H. Iizuka, G. Tamiya, and H. Inoko, “SLURP-2, a novel member of the human Ly-6 superfamily that is up-regulated in psoriasis vulgaris,” Genomics, vol. 81, no. 1, pp. 26–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. S. A. Grando, “Basic and clinical aspects of non-neuronal acetylcholine: biological and clinical significance of non-canonical ligands of epithelial nicotinic acetylcholine receptors,” Journal of Pharmacological Sciences, vol. 106, no. 2, pp. 174–179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Arredondo, A. I. Chernyavsky, R. J. Webber, and S. A. Grando, “Biological effects of SLURP-1 on human keratinocytes,” Journal of Investigative Dermatology, vol. 125, no. 6, pp. 1236–1241, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Arredondo, A. I. Chernyavsky, D. L. Jolkovsky, R. J. Webber, and S. A. Grando, “SLURP-2: a novel cholinergic signaling peptide in human mucocutaneous epithelium,” Journal of Cellular Physiology, vol. 208, no. 1, pp. 238–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Pettersson, G. Nylund, A. Khorram-Manesh, S. Nordgren, and D. S. Delbro, “Nicotine induced modulation of SLURP-1 expression in human colon cancer cells,” Autonomic Neuroscience: Basic and Clinical, vol. 148, no. 1-2, pp. 97–100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Nilsson, K. Forsbeck, M. Gidlund et al., “Surface characteristics of the U-937 human histiocytic lymphoma cell line: specific changes during inducible morphologic and functional differentiation in vitro,” Hamatologie und Bluttransfusion, vol. 26, pp. 215–221, 1981. View at Google Scholar · View at Scopus
  50. A. I. Chernyavsky, J. Arredondo, D. J. Putney, J. S. Marsh, and S. A. Grando, “Potential role for epithelial nicotinic receptors in tobacco related oral and lung cancers,” Journal of Stomatological Investigation, vol. 2, no. 1, pp. 5–14, 2008. View at Google Scholar
  51. S. Dionne, F. M. Ruemmele, and E. G. Seidman, “Immunopathogenesis of inflammatory bowel disease: role of cytokines and immune cell-enterocyte interactions,” Nestle Nutrition Workshop Series. Clinical & Performance Programme, vol. 2, pp. 41–61, 1999. View at Google Scholar · View at Scopus
  52. E. Cario, “Toll-like receptors in inflammatory bowel diseases: a decade later,” Inflammatory Bowel Diseases, vol. 16, no. 9, pp. 1583–1597, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. S. C. Gribar, R. J. Anand, C. P. Sodhi, and D. J. Hackam, “The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation,” Journal of Leukocyte Biology, vol. 83, no. 3, pp. 493–498, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Akhtar, J. L. Watson, A. Nazli, and D. M. McKay, “Bacterial DNA evokes epithelial IL-8 production by a MAPK-dependent, NF-kappaB-independent pathway,” The FASEB Journal, vol. 17, no. 10, pp. 1319–1321, 2003. View at Google Scholar · View at Scopus
  55. P. S. Bridger, M. Mohr, I. Stamm et al., “Primary bovine colonic cells: a model to study strain-specific responses to Escherichia coli,” Veterinary Immunology and Immunopathology, vol. 137, no. 1-2, pp. 54–63, 2010. View at Google Scholar
  56. C. Sodhi, R. Levy, R. Gill et al., “DNA attenuates enterocyte Toll-like receptor 4-mediated intestinal mucosal injury after remote trauma,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 300, no. 5, pp. G862–G873, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Levin and O. Shibolet, “Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory,” World Journal of Gastroenterology, vol. 14, no. 33, pp. 5149–5153, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. A. I. Chernyavsky, M. Kalantari-Dehaghi, C. Phillips, S. Marchenko, and S. A. Grando, “Novel cholinergic peptides SLURP-1 and -2 regulate epithelialization of cutaneous and oral wounds,” Wound Repair and Regeneration, vol. 20, no. 1, pp. 103–113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. A. I. Chernyavsky, S. Marchenko, C. Phillips, and S. A. Grando, “Auto/paracrine nicotinergic peptides participate in cutaneous stress response to wounding,” Dermato-Endocrinology, vol. 4, no. 3, pp. 324–330, 2012. View at Publisher · View at Google Scholar
  60. Y. Moriwaki, K. Yoshikawa, H. Fukuda, Y. X. Fujii, H. Misawa, and K. Kawashima, “Immune system expression of SLURP-1 and SLURP-2, two endogenous nicotinic acetylcholine receptor ligands,” Life Sciences, vol. 80, no. 24-25, pp. 2365–2368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. B. H. Lee, S. Choi, T. Shin et al., “Quercetin enhances human α7 nicotinic acetylcholine receptor-mediated ion current through interactions with Ca2+ binding sites,” Molecules and Cells, vol. 30, no. 3, pp. 245–253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. B. H. Lee, S. H. Choi, T. J. Shin et al., “Effects of quercetin on α9α10 nicotinic acetylcholine receptor-mediated ion currents,” European Journal of Pharmacology, vol. 650, no. 1, pp. 79–85, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. B. H. Lee, S. H. Hwang, S. H. Choi et al., “Quercetin inhibits α3β4 nicotinic acetylcholine receptor-mediated ion currents expressed in Xenopus oocytes,” Korean Journal of Physiology and Pharmacology, vol. 15, no. 1, pp. 17–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. L. Shih, H. Liu, C. Chen et al., “Combination treatment with luteolin and quercetin enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down-regulating nicotinic acetylcholine receptors,” Journal of Agricultural and Food Chemistry, vol. 58, no. 1, pp. 235–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Comalada, D. Camuesco, S. Sierra et al., “In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-κB pathway,” European Journal of Immunology, vol. 35, no. 2, pp. 584–592, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. H. H. Kim, H. Kong, B. Choi et al., “Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease,” Pharmaceutical Research, vol. 22, no. 9, pp. 1499–1509, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. J. P. Van Dijk, G. S. Madretsma, Z. J. Keuskamp, and F. J. Zijlstra, “Nicotine inhibits cytokine synthesis by mouse colonic mucosa,” European Journal of Pharmacology, vol. 278, no. 1, pp. R11–R12, 1995. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Spoettl, C. Paetzel, H. Herfarth et al., “(E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa,” International Journal of Colorectal Disease, vol. 22, no. 3, pp. 303–312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. W. J. de Jonge and L. Ulloa, “The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation,” British Journal of Pharmacology, vol. 151, no. 7, pp. 915–929, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. R. Eliakim and F. Karmeli, “Divergent effects of nicotine administration on cytokine levels in rat small bowel mucosa, colonic mucosa, and blood,” Israel Medical Association Journal, vol. 5, no. 3, pp. 178–180, 2003. View at Google Scholar · View at Scopus
  71. T. Werner and D. Haller, “Intestinal epithelial cell signalling and chronic inflammation: from the proteome to specific molecular mechanisms,” Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, vol. 622, no. 1-2, pp. 42–57, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. K. Matsunaga, T. W. Klein, H. Friedman, and Y. Yamamoto, “Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine,” Journal of Immunology, vol. 167, no. 11, pp. 6518–6524, 2001. View at Google Scholar · View at Scopus
  73. E. P. van der Zanden, S. A. Snoek, S. E. Heinsbroek et al., “Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor α4β2,” Gastroenterology, vol. 137, no. 3, pp. 1029–1039, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. I. Murakami, Y. Hamada, S. Yamane, H. Fujino, S. Horie, and T. Murayama, “Nicotine-induced neurogenic relaxation in the mouse colon: changes with dextran sodium sulfate-induced colitis,” Journal of Pharmacological Sciences, vol. 109, no. 1, pp. 128–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Eliakim, X. F. Qiu, and M. W. Babyatsky, “Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice,” European Journal of Gastroenterology and Hepatology, vol. 14, no. 6, pp. 607–614, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Karban and R. Eliakim, “Effect of smoking on inflammatory bowel disease: is it disease or organ specific?” World Journal of Gastroenterology, vol. 13, no. 15, pp. 2150–2152, 2007. View at Google Scholar · View at Scopus
  77. F. Chimienti, R. C. Hogg, L. Plantard et al., “Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda,” Human Molecular Genetics, vol. 12, no. 22, pp. 3017–3024, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Fujii, K. Horiguchi, H. Sunaga et al., “SLURP-1, an endogenous alpha7 nicotinic acetylcholine receptor allosteric ligand, is expressed in CD205(+) dendritic cells in human tonsils and potentiates lymphocytic cholinergic activity,” Journal of Neuroimmunology, vol. 267, no. 1-2, pp. 43–49, 2014. View at Publisher · View at Google Scholar